Novocure Ltd Ord Sh (NVCR) |
|
172.38 4.1 (2.44%)
|
01-20 23:22 |
|
Open: |
169.76 |
Pre. Close: |
168.28 |
|
High:
|
175 |
Low:
|
168.55 |
|
Volume:
|
512,189 |
Market Cap:
|
17,548M |
|
|
|
|
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
175.215 - 175.865 |
175.865 - 176.388 |
|
Low:
|
166.819 - 167.626 |
167.626 - 168.275 |
|
Close:
|
171.156 - 172.415 |
172.415 - 173.426 |
|
Technical analysis |
as of: 2021-01-20 4:50:30 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 213.43 One year: 249.29 |
| Support: |
Support1: 165.08 Support2: 154.17 |
| Resistance: |
Resistance1: 182.74 Resistance2: 213.43 |
| Pivot: |
169.44 |
| Moving Average: |
MA(5): 172.82  MA(20): 169.72
MA(100): 130.89 MA(250): 94.70 |
| MACD: |
MACD(12,26): 5.37 Signal(9): 6.42 |
| Stochastic oscillator: |
%K(14,3): 52.87 %D(3): 62.00 |
| RSI: |
RSI(14): 57.41 |
| 52-week: |
High: 182.74 Low: 53.40 Change(%): 88.0 |
| Average Vol(K): |
3-Month: 112453 10-Days: 67891 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.NVCR has closed below upper band by 37.6%. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 20 Jan 2021
Check this Co-Diagnostics, Inc. (NASDAQ:CODX) Analysis Before You Invest - Stocks Register
Mon, 18 Jan 2021
Investors Take Advantage of 7.73% Gain In Biodesix, Inc. (NASDAQ:BDSX) - Stocks Register
Sat, 16 Jan 2021
Surgery Partners, Inc. (NASDAQ:SGRY)’s Share Price Jumped 1.23%, What’s Next? Here Is A Hint: Don’t Be Too Excited - Stocks Register
Sat, 16 Jan 2021
Sotera Health Company (NASDAQ:SHC): Making Its Way Up the Stock Market - Stocks Register
Fri, 15 Jan 2021
OpGen, Inc. (NASDAQ:OPGN) Stock: Looks Like A Good Investment - Stocks Register
Thu, 14 Jan 2021
XpresSpa Group, Inc. (NASDAQ:XSPA) Stock: Looks Like A Good Investment - Stocks Register
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Health Care Equipment & Services |
| Shares Out. (M) |
102 |
| Shares Float (M) |
86 |
|
% Held by Insiders
|
14.82 |
|
% Held by Institutions
|
82.91 |
|
Shares Short (K)
|
5,880 |
|
Shares Short P. Month (K)
|
5,140 |
Stock Financials |
|
EPS
|
0.180 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
3.020 |
|
Profit Margin
|
4.26 |
|
Operating Margin
|
4.18 |
|
Return on Assets (ttm)
|
2.7 |
|
Return on Equity (ttm)
|
7.7 |
|
Qtrly Rev. Growth
|
44.1 |
|
Gross Profit (p.s.)
|
2.584 |
|
Sales Per Share
|
4.417 |
|
EBITDA (p.s.)
|
0.258 |
|
Qtrly Earnings Growth
|
381.00 |
|
Operating Cash Flow (M)
|
53 |
|
Levered Free Cash Flow (M)
|
33 |
Stock Valuations |
|
PE Ratio
|
957.67 |
|
PEG Ratio
|
|
|
Price to Book value
|
57.08 |
|
Price to Sales
|
39.03 |
|
Price to Cash Flow
|
333.43 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
